Literature DB >> 16848710

Regulation of iron metabolism by hepcidin.

Elizabeta Nemeth1, Tomas Ganz.   

Abstract

Hepcidin, a peptide hormone made in the liver, is the principal regulator of systemic iron homeostasis. Hepcidin controls plasma iron concentration and tissue distribution of iron by inhibiting intestinal iron absorption, iron recycling by macrophages, and iron mobilization from hepatic stores. Hepcidin acts by inhibiting cellular iron efflux through binding to and inducing the degradation of ferroportin, the sole known cellular iron exporter. Synthesis of hepcidin is homeostatically increased by iron loading and decreased by anemia and hypoxia. Hepcidin is also elevated during infections and inflammation, causing a decrease in serum iron levels and contributing to the development of anemia of inflammation, probably as a host defense mechanism to limit the availability of iron to invading microorganisms. At the opposite side of the spectrum, hepcidin deficiency appears to be the ultimate cause of most forms of hemochromatosis, either due to mutations in the hepcidin gene itself or due to mutations in the regulators of hepcidin synthesis. The emergence of hepcidin as the pathogenic factor in most systemic iron disorders should provide important opportunities for improving their diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848710     DOI: 10.1146/annurev.nutr.26.061505.111303

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  213 in total

1.  BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice.

Authors:  Neeta Patel; Patarabutr Masaratana; Javier Diaz-Castro; Gladys O Latunde-Dada; Aakafa Qureshi; Pamela Lockyer; Molly Jacob; Matthew Arno; Pavle Matak; Ragai R Mitry; Robin D Hughes; Anil Dhawan; Cam Patterson; Robert J Simpson; Andrew T McKie
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Benefits and risks of iron supplementation in anemic neonatal pigs.

Authors:  Paweł Lipinski; Rafał R Starzyński; François Canonne-Hergaux; Barbara Tudek; Ryszard Oliński; Paweł Kowalczyk; Tomasz Dziaman; Olivier Thibaudeau; Mikołaj A Gralak; Ewa Smuda; Jarosław Woliński; Agnieszka Usińska; Romuald Zabielski
Journal:  Am J Pathol       Date:  2010-09       Impact factor: 4.307

3.  Prevalence of anemia and associations between neonatal iron status, hepcidin, and maternal iron status among neonates born to pregnant adolescents.

Authors:  Sunmin Lee; Ronnie Guillet; Elizabeth M Cooper; Mark Westerman; Mark Orlando; Tera Kent; Eva Pressman; Kimberly O O'Brien
Journal:  Pediatr Res       Date:  2015-09-18       Impact factor: 3.756

4.  Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2.

Authors:  Ivana De Domenico; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

5.  MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway.

Authors:  Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

Review 6.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

7.  Ferroportin is a manganese-responsive protein that decreases manganese cytotoxicity and accumulation.

Authors:  Zhaobao Yin; Haiyan Jiang; Eun-Sook Y Lee; Mingwei Ni; Keith M Erikson; Dejan Milatovic; Aaron B Bowman; Michael Aschner
Journal:  J Neurochem       Date:  2009-12-09       Impact factor: 5.372

8.  Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats.

Authors:  Li-Na Lu; Zhong-Ming Qian; Ka-Chun Wu; Wing-Ho Yung; Ya Ke
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

9.  The benefits of iron supplementation following blood donation vary with baseline iron status.

Authors:  Alan E Mast; Aniko Szabo; Mars Stone; Ritchard G Cable; Bryan R Spencer; Joseph E Kiss
Journal:  Am J Hematol       Date:  2020-04-15       Impact factor: 10.047

Review 10.  Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.